High Growth Tech Stocks in the US for September 2026

Over the last 7 days, the United States market has experienced a 1.6% decline, yet it remains up by 12% over the past year with earnings forecasted to grow by 17% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on future opportunities.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Fabrinet	21.15%	21.40%	★★★★★★
TG Therapeutics	21.54%	21.27%	★★★★★★
Lumentum Holdings	42.18%	92.37%	★★★★★★
Ciena	20.27%	31.06%	★★★★★★
Shopify	20.16%	21.03%	★★★★★★
Insmed	32.17%	67.15%	★★★★★★
Madrigal Pharmaceuticals	27.97%	63.67%	★★★★★★
Travere Therapeutics	24.30%	53.11%	★★★★★★
Precigen	34.82%	55.42%	★★★★★★
Snowflake	20.93%	53.68%	★★★★★★

Click here to see the full list of 24 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Ardelyx (ARDX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Ardelyx, Inc. focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market capitalization of $877.14 million.

Operations: Ardelyx generates revenue primarily from the development and commercialization of biopharmaceutical products, amounting to $450.89 million.

Ardelyx showcases robust potential in the biopharmaceutical sector with its strategic focus on innovative treatments. Despite current unprofitability, the company is poised for a significant turnaround, expecting an earnings growth of 61.5% annually. Recent activities, including presentations at major healthcare conferences and a $36 million shelf registration, underline Ardelyx's proactive approach in scaling operations and research endeavors. With revenue forecasted to grow at 23.2% per year—surpassing U.S market averages—Ardelyx is strategically positioning itself for future profitability and market leadership in addressing complex medical needs.

• Take a closer look at Ardelyx's potential here in our health report.

• Examine Ardelyx's past performance report to understand how it has performed in the past.

Travere Therapeutics (TVTX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $6.20 billion.

Operations: The company generates revenue primarily through the development and commercialization of innovative therapies, amounting to $591.33 million.

Travere Therapeutics recently highlighted its dynamic presence in the biopharmaceutical landscape through multiple conference presentations, signaling robust engagement with industry stakeholders and potential for increased visibility. Despite a challenging financial performance with a net loss widening to $34.8 million in Q2 2026 from $12.76 million the previous year, Travere's revenue surged by 47.9% to $169.58 million in the same period, reflecting significant operational growth. This uptrend is supported by strategic initiatives like the licensing agreement with Everest Medicines, poised to potentially enhance future revenue streams through milestone payments up to $1,030 million and high-tier royalties on sales of civorebrutinib, an innovative treatment for renal diseases under development.

• Get an in-depth perspective on Travere Therapeutics' performance by reading our health report here.

• Assess Travere Therapeutics' past performance with our detailed historical performance reports.

Madrigal Pharmaceuticals (MDGL)

Simply Wall St Growth Rating: ★★★★★★

Overview: Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company specializing in novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States, with a market cap of approximately $12.48 billion.

Operations: The company focuses on delivering therapeutics for MASH, generating $1.28 billion in revenue from this segment.

Madrigal Pharmaceuticals is navigating a transformative phase with significant expansions and strategic appointments, such as the inclusion of Dr. John C. Reed to its board, enhancing its R&D capabilities in critical health segments. Despite a current unprofitability with a net loss of $57.94 million in Q2 2026, the company's revenue growth forecast at 28% annually outpaces the US market average of 13.4%, signaling robust potential ahead. Furthermore, its expected earnings growth rate at an impressive 63.67% per year coupled with strategic initiatives like the siRNA partnership for liver disease treatments positions Madrigal to potentially capitalize on high-growth sectors within biopharmaceuticals, despite recent financial strains.

• Click to explore a detailed breakdown of our findings in Madrigal Pharmaceuticals' health report.

• Evaluate Madrigal Pharmaceuticals' historical performance by accessing our past performance report.

Turning Ideas Into Actions

• Discover the full array of 24 US High Growth Tech and AI Stocks right here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com